Christina Fasser

1992-2020 President Retina International

[Alliance for Vision Research @NAEVRAdvocacy]

In case you missed it, the replay of our Inherited Retinal Diseases Briefing is now available. IRDs are rare genetic conditions that can lead to progressive vision loss and blindness. https://t.co/CBSvrdHKaS

[FARPE @retinafarpe]

📲Cuando hablamos de discapacidad visual, muchas personas piensan únicamente en el bastón blanco o el braille. Sin embargo, la tecnología se ha convertido en una herramienta fundamental para acceder a la información y desenvolverse con mayor autonomía en el día a día.

[Ocugen @Ocugen]

What makes #OCU400 different?

OCU400 is designed to address multiple RP mutations through a potential one-time therapy.

Follow us for updates as we advance OCU400 toward a planned BLA submission this year.

#RetinitisPigmentosa #GeneTherapy $OCGN

[IOVS Journal @ARVOiovs]

Maximilian Pfau et al. from the University of Bonn investigate parafoveal dark adaptation in early and intermediate age-related macular degeneration.
https://t.co/z56XDfWq00

[Modern Retina @ModernRetina]

As aesthetic injectables continue to grow in popularity, retina specialists are increasingly likely to encounter patients considering these procedures. Watch the latest episode of The Retina TL;DR to learn more: https://t.co/7c6A1iDtVs

[Macular Degeneration Association @MacularHope]

Why B Vitamins Are The Cornerstone of Next-Generation AMD Supplements https://t.co/kgOJItWzNB

[Eyewire+ @eyewireplus]

FDA grants Outlook Therapeutics’ appeal for Lytenava, saying it showed substantial evidence of effectiveness in wet AMD. The company plans to resubmit its BLA in June: https://t.co/vQwCSMmp9O

[European Blind Union @euroblind]

🎙️ Let the voice of #inclusion advocates be heard! 

Tune in to our "EBU in Action" podcast and revisit interesting conversations with #disability rights promoters.

Apple Podcasts: https://t.co/axwF61Qi1F
Podbean: https://t.co/YaR11JX1Bi
Spotify: https://t.co/oJq1Zcm051

[European Blind Union @euroblind]

(1/5) ✍ Last week, EBU co-signed alongside @InclusionEurope, the @MyEDF, the European Federation of Hard of Hearing People and the @EUD_Brussels a joint letter calling on the @EU_Commission to advance #accessibility in the upcoming AVSMD revision: https://t.co/aYKVnOONr7

[National Federation of the Blind @NFB_voice]

"No one wants their child to grow up experiencing the same difficulties you experienced as a blind person," Latonya Phipps Cross said. "But, why not? If I learned to thrive as a blind person, why wasn’t that good enough for her as well?"

Read more: https://t.co/l7x7993e6I

[Belite Bio @belite_bio]

Belite Bio will present previously disclosed Phase 3 DRAGON topline results in Stargardt disease at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026).

Read more: https://t.co/pTLsY0OQX4

[Foundation Fighting Blindness @FightBlindness]

Spotlight on Stargardt Disease 👁️‍🗨️

Stargardt disease leads to the buildup of toxic vitamin A byproducts, known as lipofuscin, in retinal cells. This abnormal accumulation damages cells in the retina over time and typically results in progressive central vision loss.

As lipofuscin builds up in the macula — the part of the eye responsible for sharp central vision — everyday tasks like reading and recognizing faces can become more difficult.

Learn more about Stargardt disease at: https://t.co/sEOQjasCz8

[EURORDIS-Rare Diseases Europe @eurordis]

At the European Commission Disability Platform meeting in Cyprus, Charissa Frank called for disability assessment frameworks that reflect the realities of people living with rare, invisible, fluctuating & progressive disabilities. Read more 👉 https://t.co/KHf3z1vhc8

[Christina Fasser @FasserChristina]

Pilot Study of Patient-Reported Outcomes in Stargardt Disease: Correlation With Functional and Structural Findings https://t.co/ykxmIn5Iem

[Foundation Fighting Blindness @FightBlindness]

Our FINAL United in Vision 2026 Flash Sale starts TODAY. 🎉

Save 20% on registration for the conference happening June 12–13 in Fort Worth, Texas—but only through May 19. The hotel reservation deadline has also been extended by an additional week.

Join patients, families, researchers, clinicians, and advocates from around the world as we focus on advancing innovative research toward treatments and cures for blinding diseases. This is where our entire community comes together, and where progress moves forward.

Register now and lock in both savings before the deadline. https://t.co/ewaqPTxwWx

Video Description: Cory talking directly to the camera. Graphics appear on the screen associated with what he is saying.

[IOVS Journal @ARVOiovs]

Can Zhao et al. report that Pigment Epithelium-Derived Factor (PEDF) Prevents Corneal Endothelial Dysfunction of Fuchs Endothelial Corneal Dystrophy, https://t.co/O3NzQUM3TP.

[Eyewire+ @eyewireplus]

A study in Ophthalmology found diabetic retinopathy severity was linked to higher mortality risk in more than 524,000 patients with diabetes: https://t.co/PjzIyPelT0

[Foundation Fighting Blindness @FightBlindness]

We’re proud to celebrate José-Alain Sahel, MD, FARVO, as he receives the 2026 ARVO Proctor Medal, a highly prestigious award recognizing outstanding research in basic and clinical ophthalmologic sciences.

A global leader in retinal disease research and therapy development, Dr. Sahel’s work has helped advance groundbreaking treatments into clinical trials, bringing real progress closer for people living with blinding diseases. His impact on our community runs deep—not only through his scientific leadership, but through his long-standing partnership with the Foundation. Since 2001, he has served as a dedicated member of our Scientific Advisory Board and currently as Vice Chair, helping guide the research we fund to accelerate treatments and cures.

We’re honored to work alongside him and celebrate this well-deserved recognition. Congratulations, Dr. Sahel!

Image Description: Dark blue background. Green banner on the top left side with text that reads, "2026 ARVO Proctor Medal." Text below reads, "Recognizing outstanding research in basic and clinical ophthalmologic sciences." Dr. Sahel to the right, with text below that reads "José-Alain Sahel, MD, FARVO."

[Belite Bio @belite_bio]

We initiated a rolling NDA submission to the U.S. FDA for our investigational oral therapy for Stargardt disease type 1.

Learn more: https://t.co/cHzwL0m9q5

[Ophthalmology Times @OphthTimes]

The first patient has been enrolled in the SOL-X trial, an open-label extension designed to follow participants from earlier pivotal studies for an additional 3 years.

https://t.co/lDdljulDpJ